Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Marksans Pharma
Join Channel
Consolidated Standalone

Marksans Pharma

₹158.9 2.7 | 1.7%

Market Cap ₹7201 Cr.

Stock P/E 22.7

P/B 3.7

Current Price ₹158.9

Book Value ₹ 43.2

Face Value 1

52W High ₹185.4

Dividend Yield 0.31%

52W Low ₹ 70.2

Edit Ratio

Marksans Pharma Research see more...

Overview Inc. Year: 1992Industry: Pharmaceuticals & Drugs

Marksans Pharma Ltd, collectively with its subsidiaries, engages within the research and development, production, advertising and marketing, distribution, and sale of generic pharmaceutical formulations in North America, Europe, the UK, Australia, New Zealand, and across the world. The agency offers products in the analgesic, anti inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, ache management, neurology, hormonal, antifungal, antiulcerative, cardiovascular, vitamin, cough and cold, dermatology, gastrointestinal, cephalosporin, injectable, central nervous system, antibacterial, high blood pressure, oncology, and antibiotics and anti-allergic healing areas. It additionally offers agreement research and production offerings, as well as distributes generic pharma products. Marksans Pharma Ltd incorporated in 1992 and is headquartered in Mumbai, India.

Read More..

Marksans Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Marksans Pharma Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 361 363 418 434 453 480 486 500 531 586
Other Income 9 12 15 16 14 18 11 10 19 5
Total Income 370 375 433 450 467 497 497 510 550 591
Total Expenditure 301 305 354 361 372 403 376 398 417 453
Operating Profit 69 70 79 89 94 94 121 112 133 138
Interest 2 1 5 2 3 2 2 2 2 3
Depreciation 7 9 21 11 14 13 14 14 18 22
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 60 60 53 76 78 79 104 97 114 113
Provision for Tax 13 12 23 16 18 17 21 26 30 30
Profit After Tax 46 48 30 60 60 62 83 70 84 83
Adjustments 0 1 -2 -0 1 1 -1 -2 -0 0
Profit After Adjustments 46 49 28 60 61 63 82 69 84 83
Adjusted Earnings Per Share 1.1 1.2 0.7 1.5 1.5 1.6 1.8 1.5 1.8 1.8

Marksans Pharma Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 438 630 797 893 767 913 1000 1134 1376 1491 1852 2103
Other Income 8 7 12 13 19 8 5 0 7 42 59 45
Total Income 446 637 809 906 786 921 1005 1135 1383 1533 1911 2148
Total Expenditure 373 516 621 761 734 834 868 942 1037 1232 1513 1644
Operating Profit 74 121 188 145 52 87 137 193 346 301 399 504
Interest 15 19 16 10 7 10 10 9 8 8 9 9
Depreciation 16 16 16 28 30 27 23 27 36 45 52 68
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 44 86 156 107 15 50 104 157 302 248 338 428
Provision for Tax -5 13 44 24 4 14 24 36 64 61 72 107
Profit After Tax 49 74 112 83 11 36 80 121 239 187 265 320
Adjustments -3 -2 -3 -4 -2 -3 -4 -4 -3 -2 1 -3
Profit After Adjustments 46 72 109 79 9 33 76 117 236 185 266 318
Adjusted Earnings Per Share 1.2 1.9 2.7 1.9 0.2 0.8 1.9 2.9 5.8 4.5 5.9 6.9

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 24% 18% 15% 16%
Operating Profit CAGR 33% 27% 36% 18%
PAT CAGR 42% 30% 49% 18%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 103% 27% 47% 21%
ROE Average 19% 23% 21% 23%
ROCE Average 23% 29% 26% 27%

Marksans Pharma Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 86 142 380 454 433 471 542 636 886 1202 1745
Minority's Interest 7 7 8 8 6 10 10 13 19 21 20
Borrowings 8 20 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 3 2 1 -2 16 16 17 24 24 57 94
Total Current Liabilities 297 319 286 259 296 235 233 229 299 380 365
Total Liabilities 401 490 676 720 752 731 802 902 1228 1660 2224
Fixed Assets 156 146 166 270 267 279 270 303 309 428 486
Other Non-Current Assets 1 2 1 10 1 1 1 6 16 7 38
Total Current Assets 244 343 509 440 484 451 531 594 903 1225 1700
Total Assets 401 490 676 720 752 731 802 902 1228 1660 2224

Marksans Pharma Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 22 16 47 185 35 25 40 34 94 112 206
Cash Flow from Operating Activities 39 65 155 31 14 50 27 233 179 99 237
Cash Flow from Investing Activities -5 -4 -33 -123 -21 -39 -13 -60 -45 -84 -259
Cash Flow from Financing Activities -40 -29 17 -58 -3 3 -21 -114 -15 80 198
Net Cash Inflow / Outflow -7 31 138 -150 -10 15 -7 60 118 94 176
Closing Cash & Cash Equivalent 16 47 185 35 25 40 33 94 212 206 382

Marksans Pharma Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 1.19 1.87 2.67 1.92 0.22 0.8 1.87 2.86 5.76 4.51 5.88
CEPS(Rs) 1.67 2.32 3.13 2.71 1.01 1.53 2.52 3.6 6.71 5.66 7
DPS(Rs) 0 0.1 0.12 0.12 0.05 0.05 0.05 0.1 0.25 0.25 0.5
Book NAV/Share(Rs) 1.89 3.34 8.97 10.79 10.59 11.5 13.25 15.54 21.66 27.1 38.51
Core EBITDA Margin(%) 15.03 18.09 22.07 14.82 4.29 8.59 13.21 16.95 24.4 16.71 16.64
EBIT Margin(%) 13.26 16.75 21.58 13.1 2.83 6.58 11.4 14.63 22.28 16.53 17
Pre Tax Margin(%) 9.93 13.72 19.57 11.96 1.94 5.46 10.43 13.86 21.71 15.98 16.56
PAT Margin (%) 11.14 11.69 14.05 9.26 1.48 3.92 8.04 10.65 17.14 12.06 13.01
Cash Profit Margin (%) 14.71 14.18 16.08 12.41 5.4 6.86 10.32 13 19.74 14.95 15.55
ROA(%) 12.42 16.52 19.21 11.86 1.54 4.83 10.49 14.17 22.4 12.94 13.66
ROE(%) 0 73.02 45.15 20.45 2.59 7.92 15.88 20.49 31.33 18.72 18.59
ROCE(%) 44.72 38.3 44.64 23.16 4 10.6 18.51 25.57 39.76 23.82 22.89
Receivable days 101.6 87.17 80.88 81.87 110.59 84.88 64.51 67.57 67.57 78.56 72.63
Inventory Days 62.88 52.22 53.3 60.86 85.14 81.63 93.32 86.1 84.73 97.65 81.36
Payable days 82.77 69.07 77.93 80.92 111.69 83.59 67.39 69.55 85.57 93.88 85.31
PER(x) 3.28 12.83 23.07 24.09 218.39 39.33 13.3 4.86 8.67 10.1 11.99
Price/Book(x) 2.06 7.17 6.87 4.28 4.45 2.75 1.87 0.89 2.31 1.68 1.83
Dividend Yield(%) 0 0.42 0.19 0.26 0.11 0.16 0.2 0.72 0.5 0.55 0.71
EV/Net Sales(x) 0.71 1.67 3.06 2.19 2.63 1.5 1.08 0.44 1.35 1.04 1.36
EV/Core EBITDA(x) 4.21 8.65 12.97 13.48 38.91 15.81 7.92 2.57 5.35 5.18 6.32
Net Sales Growth(%) 23.31 43.7 26.46 12.13 -14.12 18.97 9.57 13.41 21.33 8.33 24.23
EBIT Growth(%) 147.88 81.52 62.9 -31.95 -81.47 176.93 89.88 45.59 86.93 -17.47 35.48
PAT Growth(%) 127.73 50.79 52.07 -26.1 -86.3 215.87 124.68 50.12 97.54 -21.68 42.02
EPS Growth(%) 124.49 56.72 43.22 -28.23 -88.74 272.77 132.11 53.05 101.63 -21.77 30.32
Debt/Equity(x) 1.88 1.12 0.23 0.19 0.25 0.25 0.18 0.03 0.02 0.04 0.02
Current Ratio(x) 0.82 1.07 1.78 1.7 1.63 1.92 2.28 2.59 3.02 3.22 4.65
Quick Ratio(x) 0.56 0.75 1.32 1.05 0.99 0.99 1.02 1.54 1.67 2.11 3.33
Interest Cover(x) 3.98 5.52 10.72 11.52 3.19 5.87 11.8 18.97 38.84 30.31 37.99
Total Debt/Mcap(x) 1.08 0.17 0.04 0.05 0.06 0.09 0.1 0.03 0.01 0.02 0.01

Marksans Pharma Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 48.25 48.25 48.25 48.6 49 43.85 43.85 43.85 43.85 43.85
FII 2.59 3.46 4.04 4.06 4.24 15.12 14.91 15.07 15.56 15.57
DII 0.41 0.46 0.95 0.95 0.96 1.46 3.65 4.02 4.76 5.17
Public 48.75 47.82 46.77 46.38 45.8 39.58 37.59 37.06 35.83 35.4
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 49% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23%
  • Debtor days have improved from 93.88 to 85.31days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 43.85%.
  • Stock is trading at 3.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Marksans Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!